Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 7;19(29):4679-88.
doi: 10.3748/wjg.v19.i29.4679.

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

Do Seon Song  1 , Si Hyun Bae, Myeong Jun Song, Sung Won Lee, Hee Yeon Kim, Young Joon Lee, Jung Suk Oh, Ho Jong Chun, Hae Giu Lee, Jong Young Choi, Seung Kew Yoon
Affiliations

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

Do Seon Song et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the prognostic factors and efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.

Methods: Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port. The epirubicin-cisplatin-5-fluorouracil (ECF) chemotherapeutic regimen consisted of 35 mg/m(2) epirubicin on day 1, 60 mg/m(2) cisplatin for 2 h on day 2, and 500 mg/m(2) 5-fluorouracil for 5 h on days 1-3. The treatments were repeated every 3 or 4 wk.

Results: Three (6%) of the 50 patients achieved a complete response (CR), 13 (26%) showed partial responses (PR), and 22 (44%) had stable disease (SD). The median survival and time to progression were 7 and 2 mo, respectively. After 2 cycles of HAIC, CR was achieved in 1 patient (2%), PR in 10 patients (20%) and SD in 26 patients (52%). Significant pre-treatment prognostic factors were a tumor volume of < 400 cm(3) (P = 0.01) and normal levels of protein induced by vitamin K absence or antagonist (PIVKA)-II (P = 0.022). After 2 cycles of treatment, disease control (CR + PR + SD) (P = 0.001), PVTT response (P = 0.003) and α-fetoprotein reduction of over 50% (P = 0.02) were independent factors for survival. Objective response (CR + PR), disease control, PVTT response, and combination therapy during the HAIC were also significant prognostic factors. Adverse events were tolerable and successfully managed.

Conclusion: HAIC may be an effective treatment modality for advanced HCC with PVTT in patients with tumors < 400 cm(3) and good prognostic factors.

Keywords: Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Portal vein tumor thrombosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival rate (A) and time to disease progression (B) of the patients. OS: Overall survival; TTP: Time to disease progression.
Figure 2
Figure 2
Overall survival of the objective response and disease control groups. A, B: After the second cycle of high-dose hepatic arterial infusion chemotherapy (HAIC); C, D: During HAIC.
Figure 3
Figure 3
Cumulative survival rate according to the presence of extrahepatic metastasis.
Figure 4
Figure 4
Cumulative survival rates. A: According to the pre-treatment α-fetoprotein (AFP) level; B: According to the AFP reduction after two cycles of hepatic arterial infusion chemotherapy (HAIC); C: According to the pre-treatment protein induced by vitamin K absence or antagonist (PIVKA)-II level; D: According to the PIVKA-II reduction after two cycles of HAIC.
See this image and copyright information in PMC

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
    1. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–1014. - PubMed
    1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429–442. - PubMed
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022. - PMC - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed

Publication types

MeSH terms

Supplementary concepts